Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

If approved for wide release, the pill, orforglipron, could shake up the booming GLP-1 market by offering an option that's easier to make and store than the injections that are currently available.

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

A new pill is helping people with Type 2 diabetes lose weight and lower blood sugar in a phase-three clinical trial.

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 ...

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...